Financiën AbbVie Inc.

Aandelen

ABBV

US00287Y1091

Farmaceutische producten

Beurs gesloten - Nyse Andere beurzen 19:00:02 29-11-2024			Voorbeurs 14:15:16
182,93 ^USD	-0,08%		182,90	-0,02%

22/11	AbbVie-aandelen stijgen nu Leerink Partners het aandeel opwaardeert	MT
22/11	ABBVIE INC. : Leerink Partners zet aandeel op kooplijst	ZM

Voorlopige winst- en verliesrekening: AbbVie Inc.

income-statement-evolution-chart ABBVIE-INC

Fiscaal tijdperk: Dezember	2019	2020	2021	2022	2023	2024	2025	2026
Omzet ¹	33.266	45.784	56.122	58.054	54.318	56.021	59.082	63.354
Variatie	-	37,63%	22,58%	3,44%	-6,44%	3,14%	5,46%	7,23%
EBITDA ¹	17.747	22.642	29.018	30.961	25.545	25.855	28.759	31.751
Variatie	-	27,58%	28,16%	6,7%	-17,49%	1,22%	11,23%	10,41%
Bedrijfsresultaat (EBIT) ¹	15.730	21.976	28.215	30.183	24.793	24.931	27.837	30.824
Variatie	-	39,71%	28,39%	6,98%	-17,86%	0,56%	11,65%	10,73%
Betaalde rente ¹	-1.509	-2.280	-2.384	-2.044	-1.684	-2.186	-2.329	-2.133
Resultaat voor belastingen (EBT) ¹	8.426	3.398	12.989	13.477	6.250	10.647	14.948	16.757
Variatie	-	-59,67%	282,25%	3,76%	-53,62%	70,36%	40,39%	12,1%
Nettowinst (verlies) ¹	7.882	4.616	11.542	11.836	4.863	8.250	11.969	14.572
Variatie	-	-41,44%	150,04%	2,55%	-58,91%	69,65%	45,08%	21,74%
Datum van publicatie	7/02/20	3/02/21	2/02/22	9/02/23	2/02/24	-	-	-

¹USD in Miljoen

Geschatte gegevens

Fiscaal tijdperk: December	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4
Omzet ¹	8.704	8.619	10.425	12.882	13.858	12.935	13.959	14.342	14.886	13.538	14.583	14.812	15.121	12.225	13.865	13.927	14.301	12.310	14.462	14.460	14.805	13.184	14.888	15.284	15.700
Variatie	-	-0,98%	20,95%	23,57%	7,58%	-6,66%	7,92%	2,74%	3,79%	-9,06%	7,72%	1,57%	2,09%	-19,15%	13,42%	0,45%	2,69%	-13,92%	17,48%	-0,01%	2,39%	-10,95%	12,93%	2,66%	2,72%
EBITDA ¹	4.394	4.407	5.054	6.459	6.722	6.808	7.145	7.559	7.506	7.156	7.643	8.090	8.072	5.682	6.710	6.706	6.447	5.378	6.342	6.937	7.043	6.055	7.410	7.305	7.374
Variatie	-	0,3%	14,68%	27,8%	4,07%	1,28%	4,95%	5,79%	-0,7%	-4,66%	6,81%	5,85%	-0,22%	-29,61%	18,09%	-0,06%	-3,86%	-16,58%	17,92%	9,38%	1,53%	-14,03%	22,38%	-1,42%	0,94%
Bedrijfsresultaat (EBIT) ¹	3.885	4.292	4.905	6.284	6.495	6.602	6.944	7.336	7.333	6.958	7.440	7.909	7.876	5.503	6.520	6.510	6.260	5.195	6.158	6.746	6.826	6.237	7.104	7.268	7.423
Variatie	-	10,48%	14,28%	28,11%	3,36%	1,65%	5,18%	5,65%	-0,04%	-5,11%	6,93%	6,3%	-0,42%	-30,13%	18,48%	-0,15%	-3,84%	-17,01%	18,54%	9,55%	1,19%	-8,63%	13,9%	2,31%	2,13%
Charge d'intérêts ¹	-455	-428	-484	-620	-618	-622	-606	-585	-571	-539	-532	-497	-476	-454	-454	-398	-378	-453	-506	-591	-653	-612	-592	-533	-513
Resultaat voor belastingen (EBT) ¹	-	-	-	-	-	-	-	-	-	-	-	-	-	475	2.610	1.953	1.212	1.755	2.146	2.084	3.366	-	-	-	-
Variatie	-	-	-	-	-	-	-	-	-	-	-	-	-	-	449,47%	-25,17%	-37,94%	44,8%	22,28%	-2,89%	61,54%	-100%	-	-	-
Nettowinst (verlies) ¹	2.801	3.010	-738	2.308	36	3.553	766	3.179	4.044	4.490	924	3.949	2.473	239	2.024	1.778	822	1.369	1.370	1.561	2.623	1.418	1.766	1.999	2.282
Variatie	-	7,46%	-	-	-98,44%	9.769,44%	-78,44%	315,01%	27,21%	11,03%	-79,42%	327,38%	-37,38%	-90,34%	746,86%	-12,15%	-53,77%	66,55%	0,07%	13,94%	68,05%	-45,94%	24,54%	13,19%	14,16%
Datum van publicatie	7/02/20	1/05/20	31/07/20	30/10/20	3/02/21	30/04/21	30/07/21	29/10/21	2/02/22	29/04/22	29/07/22	28/10/22	9/02/23	27/04/23	27/07/23	27/10/23	2/02/24	26/04/24	25/07/24	30/10/24	-	-	-	-	-

¹USD in Miljoen

Geschatte gegevens

Balansprognose: AbbVie Inc.

Fiscaal tijdperk: December	2019	2020	2021	2022	2023	2024	2025	2026
Nettoschuld ¹	26.804	77.607	66.854	54.042	46.571	57.629	48.733	38.300
Variatie	-	189,54%	-13,86%	-19,16%	-13,82%	23,74%	-15,44%	-21,41%
Datum van publicatie	7/02/20	3/02/21	2/02/22	9/02/23	2/02/24	-	-	-

¹USD in Miljoen

Geschatte gegevens

Verwachte kasstroom: AbbVie Inc.

Fiscaal tijdperk: December	2019	2020	2021	2022	2023	2024	2025	2026
CAPEX ¹	552	798	787	695	777	852,9	873	906,8
Variatie	-	44,57%	-1,38%	-11,69%	11,8%	9,76%	2,36%	3,87%
Vrije kasstroom (FCF) ¹	12.772	16.790	21.990	24.248	22.062	17.411	24.922	26.581
Variatie	-	31,46%	30,97%	10,27%	-9,02%	-21,08%	43,14%	6,66%
Datum van publicatie	7/02/20	3/02/21	2/02/22	9/02/23	2/02/24	-	-	-

¹USD in Miljoen

Geschatte gegevens

Verwachte financiële ratio's: AbbVie Inc.

Fiscaal tijdperk: December	2019	2020	2021	2022	2023	2024	2025	2026
Winstgevendheid
EBITDA-marge (%)	53,35%	49,45%	51,71%	53,33%	47,03%	46,15%	48,68%	50,12%
EBIT-marge (%)	47,29%	48%	50,27%	51,99%	45,64%	44,5%	47,12%	48,65%
EBT-marge (%)	25,33%	7,42%	23,14%	23,21%	11,51%	19,01%	25,3%	26,45%
Nettomarge (%)	23,69%	10,08%	20,57%	20,39%	8,95%	14,73%	20,26%	23%
FCF-marge (%)	38,39%	36,67%	39,18%	41,77%	40,62%	31,08%	42,18%	41,96%
Vrije kasstroom/nettoresultaat (%)	162,04%	363,73%	190,52%	204,87%	453,67%	211,04%	208,22%	182,42%
Winstgevendheid
ROA	10,62%	3,85%	15,28%	17,24%	14,46%	8,97%	11,15%	13,86%
ROE	-160,36%	188,25%	159,36%	150,62%	143,18%	196,29%	250,75%	249,87%
Financiële gezondheid
Hefboom (schuld/ebitda)	1,51x	3,43x	2,3x	1,75x	1,82x	2,23x	1,69x	1,21x
Schuld/vrije kasstroom	2,1x	4,62x	3,04x	2,23x	2,11x	3,31x	1,96x	1,44x
Kapitaalintensiteit
Kapitaaluitgaven/omzet (%)	1,66%	1,74%	1,4%	1,2%	1,43%	1,52%	1,48%	1,43%
CAPEX / EBITDA (%)	3,11%	3,52%	2,71%	2,24%	3,04%	3,3%	3,04%	2,86%
CAPEX / FCF (%)	4,32%	4,75%	3,58%	2,87%	3,52%	4,9%	3,5%	3,41%
Bestanddelen per aandeel
Kasstroom per aandeel ¹	8,978	10,51	12,82	14,03	12,88	12,24	15,11	14,21
Variatie	-	17,09%	21,92%	9,45%	-8,18%	-5,01%	23,48%	-5,98%
Dividend per aandeel ¹	4,39	4,84	5,31	5,71	5,99	6,233	6,53	6,826
Variatie	-	10,25%	9,71%	7,53%	4,9%	4,06%	4,76%	4,53%
Nettoactief per aandeel ¹	-5,507	7,828	8,713	9,743	5,843	4,78	5,918	7,916
Variatie	-	-242,16%	11,3%	11,82%	-40,03%	-18,19%	23,81%	33,76%
WPA ¹	5,28	2,72	6,45	6,63	2,72	4,752	7,196	8,897
Variatie	-	-48,48%	137,13%	2,79%	-58,97%	74,7%	51,44%	23,63%
Aantal aandelen (in duizend)	1.478.821	1.765.474	1.767.880	1.767.880	1.765.537	1.767.140	1.767.140	1.767.140
Datum van publicatie	7/02/20	3/02/21	2/02/22	9/02/23	2/02/24	-	-	-